Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00025779 · ClinicalTrials.gov registry record · NA

Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders

A NA study, sponsored by National Institute of Mental Health (NIMH).

Completed
Registry status
NA
Development phase
60
Enrollment target

NCT00025779 is a NA study that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 60 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00025779, a NA study, has completed, sponsored by National Institute of Mental Health (NIMH).

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target

Study Summary

This study will evaluate the efficacy and safety of methylphenidate for treating hyperactivity, impulsiveness, and distractibility in 60 children and adolescents with Pervasive Developmental Disorders (PDD). Methylphenidate (Ritalin)is approved by the Food and Drug Administration for the treatment of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Data supporting its safety and effectiveness in treating ADHD symptoms in PDD are limited. Children and adolescents who do not show a positive response to methylphenidate will be invited to participate in a pilot study of the non-stimulant medication guanfacine (Tenex).

Interventions

  • DRUG methylphenidate
  • DRUG guanfacine

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2001-10
Phase NA

What the Registry Record Tells You About NCT00025779

The ClinicalTrials.gov registry entry for NCT00025779 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which methylphenidate is the first listed.

NCT00025779 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00025779 about?

NCT00025779 is a clinical study titled "Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders". This study will evaluate the efficacy and safety of methylphenidate for treating hyperactivity, impulsiveness, and distractibility in 60 children and adolescents with Pervasive Developmental Disorders (PDD). Methylphenidate (Ritalin)is approved by the Food and Drug Administration for the treatment o...

What is the current status of trial NCT00025779?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2001-10.

What interventions are being tested in trial NCT00025779?

The interventions under investigation include: methylphenidate (DRUG), guanfacine (DRUG).

Who is sponsoring clinical trial NCT00025779?

This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.